Pharmacokinetic and clinical improvements after PK-guided switch from standard half-life to extended half-life factor VIII products.

[1]  J. Poveda-Andrés,et al.  Monitoring coagulation factors during surgery. A systematic review. , 2021, Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria.

[2]  B. Kerlin,et al.  Decreased Bleeding Rates in Patients with Hemophilia A Switching from Standard-Half-Life FVIII to BAY 94-9027 Prophylaxis , 2020, Thrombosis and Haemostasis.

[3]  O. Stasyshyn,et al.  Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: Results from the phase 3 PROPEL study. , 2020, Blood.

[4]  A. Iorio,et al.  Direct comparison of two extended half-life PEGylated recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A , 2020, Annals of Hematology.

[5]  E. Santagostino,et al.  WFH Guidelines for the Management of Hemophilia, 3rd edition , 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

[6]  D. Rubio-Rodríguez,et al.  Cost of patients with hemophilia A treated with standard half-life or extended half-life FVIII in Spain , 2020, Expert review of pharmacoeconomics & outcomes research.

[7]  J. Johnsen,et al.  Biological mechanisms underlying inter‐individual variation in factor VIII clearance in haemophilia , 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

[8]  S. Parikh,et al.  The Australian experience with switching to extended half‐life factor VIII and IX concentrates: On behalf of the Australian Haemophilia Centre Directors' Organisation , 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

[9]  A. Harroche,et al.  Real Life Population Pharmacokinetics Modelling of Eight Factors VIII in Patients with Severe Haemophilia A: Is It Always Relevant to Switch to an Extended Half-Life? , 2020, Pharmaceutics.

[10]  S. Milligan,et al.  A Retrospective Observational Study of Rurioctocog Alfa Pegol in Clinical Practice in the United States , 2020, Journal of managed care & specialty pharmacy.

[11]  A. Iorio,et al.  Multicentre pharmacokinetic evaluation of rFVIII‐Fc (efmoroctocog alfa) in a real life and comparison with non‐extended half‐life FVIII concentrates , 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

[12]  V. Blanchette,et al.  Measuring the impact of changing from standard half‐life (SHL) to extended half‐life (EHL) FVIII prophylaxis on health‐related quality of life (HRQoL) in boys with moderate/severe haemophilia A: Lessons learned with the CHO‐KLAT tool , 2019, Haemophilia : the official journal of the World Federation of Hemophilia.

[13]  P. Chowdary.  Extended half-life recombinant products in haemophilia clinical practice - Expectations, opportunities and challenges. , 2019, Thrombosis research.

[14]  M. Holland,et al.  HOw Patients view Extended half‐life products: Impressions from real‐world experience (The HOPE study) , 2019, Haemophilia : the official journal of the World Federation of Hemophilia.

[15]  A. Iorio,et al.  Comparative pharmacokinetics of two extended half‐life FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia A: Is there a difference? , 2019, Journal of thrombosis and haemostasis : JTH.

[16]  E. Neufeld,et al.  Regional variation and cost implications of prescribed extended half‐life factor concentrates among U.S. Haemophilia Treatment Centres for patients with moderate and severe haemophilia , 2019, Haemophilia : the official journal of the World Federation of Hemophilia.

[17]  A. Iorio,et al.  Direct comparison of two extended-half-life recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A , 2019, Annals of Hematology.

[18]  K. Batt,et al.  Matching-adjusted indirect comparisons of annualized bleeding rate and utilization of BAY 94-9027 versus three recombinant factor VIII agents for prophylaxis in patients with severe hemophilia A , 2019, Journal of blood medicine.

[19]  B. Tortella,et al.  Real-World Analysis of Dispensed International Units of Coagulation Factor VIII and Resultant Expenditures for Hemophilia A Patients: A Comparison Between Standard Half-Life and Extended Half-Life Products. , 2018, Managed care.

[20]  A. Iorio,et al.  Pharmacokinetics and the transition to extended half‐life factor concentrates: communication from the SSC of the ISTH , 2018, Journal of thrombosis and haemostasis : JTH.

[21]  C. Hermans,et al.  Pharmacokinetic modelling and validation of the half‐life extension needed to reduce the burden of infusions compared with standard factor VIII , 2018, Haemophilia.

[22]  C. Hermans,et al.  Defining extended half‐life rFVIII—A critical review of the evidence , 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

[23]  C. Wang,et al.  Clinical use of recombinant factor VIII Fc and recombinant factor IX Fc in patients with haemophilia A and B , 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

[24]  J. Dumont,et al.  Improved joint health in subjects with severe haemophilia A treated prophylactically with recombinant factor VIII Fc fusion protein , 2018, Haemophilia.

[25]  E. Neufeld,et al.  Estimating and interpreting the pharmacokinetic profiles of individual patients with hemophilia A or B using a population pharmacokinetic approach: communication from the SSC of the ISTH , 2017, Journal of thrombosis and haemostasis : JTH.

[26]  A. Iorio,et al.  Switching to extended half‐life products in Canada – preliminary data , 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

[27]  A. Iorio,et al.  Development of a Web-Accessible Population Pharmacokinetic Service—Hemophilia (WAPPS-Hemo): Study Protocol , 2016, JMIR research protocols.

[28]  A. Iorio,et al.  Data Analysis Protocol for the Development and Evaluation of Population Pharmacokinetic Models for Incorporation Into the Web-Accessible Population Pharmacokinetic Service - Hemophilia (WAPPS-Hemo) , 2016, JMIR research protocols.

[29]  K. Pasi,et al.  The use of enhanced half‐life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO , 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

[30]  E. Berntorp,et al.  Prophylaxis for Hemophilia in the Era of Extended Half-Life Factor VIII/Factor IX Products , 2016, Seminars in Thrombosis & Hemostasis.

[31]  B. Konkle,et al.  Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A. , 2015, Blood.

[32]  M. Schemper,et al.  Parameters influencing FVIII pharmacokinetics in patients with severe and moderate haemophilia A , 2015, Haemophilia : the official journal of the World Federation of Hemophilia.

[33]  R. Ljung,et al.  Definitions in hemophilia: communication from the SSC of the ISTH , 2014, Journal of thrombosis and haemostasis : JTH.

[34]  M. Reding,et al.  Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A , 2014, Journal of thrombosis and haemostasis : JTH.

[35]  D. Viuff,et al.  Enhancing the pharmacokinetic properties of recombinant factor VIII: first‐in‐human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A , 2013, Journal of thrombosis and haemostasis : JTH.

[36]  J. Dumont,et al.  Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients. , 2012, Blood.

[37]  G. Spotts,et al.  Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight. , 2012, Blood.

[38]  L. Mantovani,et al.  A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study) , 2011, Journal of thrombosis and haemostasis : JTH.

[39]  Alan R. Cohen,et al.  Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. , 2007, The New England journal of medicine.

[40]  H. Pettersson,et al.  Twenty‐five years' experience of prophylactic treatment in severe haemophilia A and B , 1992, Journal of internal medicine.

[41]  Å. Ahlberg.  Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B. , 1965, Acta orthopaedica Scandinavica. Supplementum.